CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd (CLGN) Q4 2023 Earnings Call Transcript Highlights: A Year of ...
Buy Rating Affirmed for Collplant Holdings on Strong Financials and Promising Product Pipeline Advancements
Earnings Call Summary | Collplant(CLGN.US) Q4 2023 Earnings Conference
The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript:Financial Performance:CollPlant reported Q4 2023 revenues of $299,000, an increase from $58,000
CollPlant Biotechnologies' Strong Financial and R&D Progress
CollPlant Biotechnologies Q4 Adj EPS $(0.35) Misses $(0.07) Estimate, Sales $299.00K Miss $8.56M Estimate
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly Adj losses of $(0.35) per share which missed the analyst consensus estimate of $(0.07) by 400 percent. This is unchanged from the same period
Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN
Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN
CollPlant Biotechnologies Reports 2023 GAAP Revenues Of $11M, Up By $10.7M From Last Year
CollPlant Biotechnologies Reports 2023 GAAP Revenues Of $11M, Up By $10.7M From Last Year
Collplant Biotechnologies Ends 2023 With $26.7M in Cash and Cash Equivalents >CLGN
Collplant Biotechnologies Ends 2023 With $26.7M in Cash and Cash Equivalents >CLGN
Earnings Scheduled For April 4, 2024
Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. • Trinity Biotech (NASDAQ:TRIB) is projected to r
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
CollPlant Progresses in Regenerative Medicine, Highlights Key Developments
CollPlant Issues Letter to Shareholders
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
REHOVOT, Israel, Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no
CollPlant Biotechnologies Begins Preclinical Trial With Commercial-Size, Regenerative Breast Implants
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript
Earnings Call: CollPlant Biotechnologies Q3 2023 Results Highlight Resilience Amid Conflict, Focus on Regenerative Medicine
Analysts' Top Healthcare Picks: Collplant Holdings (CLGN), UnitedHealth (UNH)
HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $11 price target.
No Data